Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

MBSR en NLP, borstvoeding na de bevalling en depressie (postpartum)

30 oktober 2026 bijgewerkt door: Aysegul Kilicli

het effect van MBSR- en NLP-toepassingen op vermoeidheid, slaapkwaliteit, borstvoeding en postpartumdepressie in de postpartumperiode na een keizersnede

The postnatal period is a risky period in which mothers experience regressive and progressive changes and rapid biopsychosocial changes. Since this process affects not only the mother but also the family, mothers are under intense stress due to adaptation to the changes that occur in this period.

Studie Overzicht

Gedetailleerde beschrijving

The postnatal period is a risky period in which retrogressive and progressive changes and rapid biopsychosocial changes occur in mothers. Since this process affects not only the mother but also the family, mothers are under intense stress due to adaptation to the changes occurring in this period. Studies have reported that the most common physical problems in the early postpartum period after caesarean section are pain in the incision area, difficulty in caring for the baby alone, activity intolerance, fatigue, insomnia, breastfeeding problems (such as nipple or lack of milk), mastitis and abdominal tension/gas. As important as it is to reduce postpartum symptoms after caesarean section, it is also important to support and maintain breastfeeding. However, postpartum symptoms such as pain, fatigue and negative effects of anaesthesia after caesarean section negatively affect the breastfeeding process and lead to a delay in the onset of lactation.

When the literature was examined, no study was found that examined the effects of mindfulness-based stress reduction programme and neurolinguistic programme on fatigue, sleep quality, lactation and depression in the postpartum long term.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

90

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Eyalet/Yerleşke
      • Sanliurfa, Eyalet/Yerleşke, Turkije (Türkiye), 63000
        • Şanlıurfa training and research hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

19 jaar tot 35 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • 19-35 years old
  • caesarean section
  • primiparous
  • breastfeeding women

Exclusion Criteria:

  • women who refused to participate in the research.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Mindfulness-based stress reduction program

MBSR; Mindfulness-based stress reduction program. 8 weeks of practice once a week for 20 minutes each. Mindfulness-based stress reduction practices will be carried out online. Mothers will actively participate.

20 minutes once a week for 8 weeks

Andere namen:
  • MBSR mindfulness-gebaseerd stressreductieprogramma
Experimenteel: Neurolinguistic programming

NLP; Neurolinguistic programming 8 weeks of practice once a week for 20 minutes each. Neurolinguistic programming will be carried out online. Mothers will actively participate.

NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks

Andere namen:
  • NLP Neurolinguïstisch programmeren
Experimenteel: control

control; MBSR and NLP applications will not be performed. Mothers will be monitored online every week.

control group, no practice,

Andere namen:
  • controlegroep

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Visual Analogue Scale for Fatigue (VAS-F)
Tijdsspanne: before the first application

Visual Analogue Scale for Fatigue (VAS-F), The most positive expression of the fatigue sub-dimension is 0 and the most negative expression is 10, the most negative expression of the energy sub-dimension is 0 and the most positive expression is 10.

before the first application
Visual Analogue Scale for Fatigue (VAS-F)
Tijdsspanne: Week 4, following the intervention administered on that day

Visual Analogue Scale for Fatigue (VAS-F) The most positive expression of the fatigue sub-dimension is 0 and the most negative expression is 10, the most negative expression of the energy sub-dimension is 0 and the most positive expression is 10.

Week 4, following the intervention administered on that day
Visual Analogue Scale for Fatigue (VAS-F)
Tijdsspanne: Week 8, following the final intervention

Visual Analogue Scale for Fatigue (VAS-F) The most positive expression of the fatigue sub-dimension is 0 and the most negative expression is 10, the most negative expression of the energy sub-dimension is 0 and the most positive expression is 10.

Week 8, following the final intervention
Pittsburgh Sleep Quality Index (PSQI)
Tijdsspanne: before the first application

Pittsburgh Sleep Quality Index (PSQI) Each item is evaluated as 0-3 points and the sum of the 7 subcomponents constitutes the PDQI score. The lowest score of the scale is 0 and the highest score is 21. A total PDQI score of ≤5 indicates good sleep and >5 indicates poor sleep.

before the first application
Pittsburgh Sleep Quality Index (PSQI)
Tijdsspanne: week 4, following the intervention administered on that day

Pittsburgh Sleep Quality Index (PSQI) Each item is evaluated as 0-3 points and the sum of the 7 subcomponents constitutes the PDQI score. The lowest score of the scale is 0 and the highest score is 21. A total PDQI score of ≤5 indicates good sleep and >5 indicates poor sleep.

week 4, following the intervention administered on that day
Pittsburgh Sleep Quality Index (PSQI)
Tijdsspanne: week 8, , following the final intervention

Pittsburgh Sleep Quality Index (PSQI) Each item is evaluated as 0-3 points and the sum of the 7 subcomponents constitutes the PDQI score. The lowest score of the scale is 0 and the highest score is 21. A total PDQI score of ≤5 indicates good sleep and >5 indicates poor sleep.

week 8, , following the final intervention
Edinburgh Postpartum Depression Scale (EPDS)
Tijdsspanne: before the first application

Edinburgh Postpartum Depression Scale (EPDS) The scale is a 4-point Likert-type scale consisting of 10 items. Responses consisting of four options are scored between 0 and 3. A minimum of 0 and a maximum of 30 points can be obtained from the scale. The cut-off point of the scale is 13 points and above for women and 10 points and above for men, and above this point indicates the presence of depression.

before the first application
Edinburgh Postpartum Depression Scale (EPDS)
Tijdsspanne: week 4, following the intervention administered on that day

Edinburgh Postpartum Depression Scale (EPDS) The scale is a 4-point Likert-type scale consisting of 10 items. Responses consisting of four options are scored between 0 and 3. A minimum of 0 and a maximum of 30 points can be obtained from the scale. The cut-off point of the scale is 13 points and above for women and 10 points and above for men, and above this point indicates the presence of depression.

week 4, following the intervention administered on that day
Edinburgh Postpartum Depression Scale (EPDS)
Tijdsspanne: week 8, following the final intervention

Edinburgh Postpartum Depression Scale (EPDS) The scale is a 4-point Likert-type scale consisting of 10 items. Responses consisting of four options are scored between 0 and 3. A minimum of 0 and a maximum of 30 points can be obtained from the scale. The cut-off point of the scale is 13 points and above for women and 10 points and above for men, and above this point indicates the presence of depression.

week 8, following the final intervention
Breastfeeding Self-Efficacy Scale (BSES)
Tijdsspanne: before the first application

Breastfeeding Self-Efficacy Scale (BSES) The scale consists of 14 items, five-point Likert type. The items of the scale are evaluated on a scale from '1=never sure' to 5=always sure'. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

before the first application
Breastfeeding Self-Efficacy Scale (BSES)
Tijdsspanne: week 4, following the intervention administered on that day

Breastfeeding Self-Efficacy Scale (BSES) The scale consists of 14 items, five-point Likert type. The items of the scale are evaluated on a scale from '1=never sure' to 5=always sure'. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

week 4, following the intervention administered on that day
Breastfeeding Self-Efficacy Scale (BSES)
Tijdsspanne: week 8, following the final intervention

Breastfeeding Self-Efficacy Scale (BSES) The scale consists of 14 items, five-point Likert type. The items of the scale are evaluated on a scale from '1=never sure' to 5=always sure'. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

week 8, following the final intervention
Exclusive breastfeeding status
Tijdsspanne: before the first application

Exclusive breastfeeding status (yes or no)

before the first application
Exclusive breastfeeding status
Tijdsspanne: week 4, following the intervention administered on that day

Exclusive breastfeeding status (yes or no)

week 4, following the intervention administered on that day
Exclusive breastfeeding status
Tijdsspanne: week 8, following the final intervention

Exclusive breastfeeding status (yes or no)

week 8, following the final intervention

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: AYŞEGÜL KILIÇLI, Dr., Muş Alparslan University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

8 oktober 2024

Primaire voltooiing (Werkelijk)

1 februari 2025

Studie voltooiing (Werkelijk)

1 februari 2025

Studieregistratiedata

Eerst ingediend

3 oktober 2024

Eerst ingediend dat voldeed aan de QC-criteria

3 oktober 2024

Eerst geplaatst (Werkelijk)

8 oktober 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

All

IPD-tijdsbestek voor delen

8 October 2024 - 30 October 2025

IPD-toegangscriteria voor delen

8 October 2024 - 30 October 2025

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren